Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in first human test

NCT ID NCT06147037

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is safe, how it spreads in the body, and what dose might work best.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a radioactive drug (actinium-225 attached to a targeting antibody) that delivers radiation directly to cancer cells
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 70 participants, so safety and the right dose are still being figured out. The radioactive drug may cause side effects and may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Palo Alto, California, 94304, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Omaha, Nebraska, 68130, United States

  • Research Site

    Cleveland, Ohio, 44195, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Seattle, Washington, 98109, United States

  • Research Site

    Montreal, Quebec, H2X 0A9, Canada

  • Research Site

    Sherbrooke, Quebec, J1H 5N4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.